1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19496
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFountzilas, G.en
dc.contributor.authorKourea, H. P.en
dc.contributor.authorBobos, M.en
dc.contributor.authorTelevantou, D.en
dc.contributor.authorKotoula, V.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorPapazisis, K. T.en
dc.contributor.authorTimotheadou, E.en
dc.contributor.authorEfstratiou, I.en
dc.contributor.authorKoutras, A.en
dc.contributor.authorPentheroudakis, G.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorMiliaras, D.en
dc.contributor.authorPetraki, K.en
dc.contributor.authorPapandreou, C. N.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorRepana, D.en
dc.contributor.authorRazis, E.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorDimopoulos, A. M.en
dc.date.accessioned2015-11-24T19:00:12Z-
dc.date.available2015-11-24T19:00:12Z-
dc.identifier.issn1791-7530-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19496-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntibodies, Monoclonal/administration & dosageen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration &en
dc.subjectdosage/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/metabolism/pathologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectIn Situ Hybridization, Fluorescenceen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Metastasisen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectRetrospective Studiesen
dc.subjectTumor Markers, Biological/*metabolismen
dc.titlePaclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluationen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21868552-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractBACKGROUND: Randomized studies have shown that bevacizumab combined with taxane-based regimens increases response rates and prolongs progression-free survival (PFS) of patients with metastatic breast cancer (MBC). However predictive or prognostic biological markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed. PATIENTS AND METHODS: Retrospectively, 124 patients with MBC treated either with paclitaxel 90 mg/m(2) weekly x12 plus bevacizumab 10 mug/kg every 2 weeks or 15 mug/kg every 3 weeks (85 patients) or paclitaxel 175 mg/m(2) plus bevacizumab 15 mug/kg every 3 weeks for 6 cycles (36 patients) were identified. Additionally, the prognostic significance of a panel of key biological markers was evaluated centrally by immunohistochemistry (IHC) in 88 evaluable patients. RESULTS: More than two thirds of the patients completed chemotherapy, as planned. The response rate was almost identical (55.3% vs. 55.6%) in the patients treated with weekly or 3-weekly paclitaxel, respectively. After a median follow-up time of 23 months, the median PFS of the study population was 13 months, while median survival had not yet been reached. Common severe adverse events were neutropenia (33%), neuropathy (18.6%) and metabolic disturbances (17.6%). The incidence of hypertension of all grades was 28.1%. High expression of vascular endothelial growth factor (VEGF) receptor 3 (VEGFR3) was associated with clinical response, while high expression of VEGFR1 was associated with poor survival. CONCLUSION: The safety and activity of the combination of bevacizumab with paclitaxel given either weekly or 3-weekly in patients with MBC is confirmed.en
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons